Opinion
Video
Author(s):
Panelists discuss how various additional treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL) are considered, including CAR-T cell therapy, immunomodulatory drugs like lenalidomide, chemoimmunotherapy regimens, and other emerging therapies, highlighting their potential roles in the evolving treatment landscape.
Video content above is prompted by the following:
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors
Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma
2 Commerce Drive
Cranbury, NJ 08512